Remove Bipolar disorder Remove Personality disorders Remove Reference
article thumbnail

Gerald Maguire, MD, Provides Tips for Differentiating Bipolar Depression From MDD

Psychiatric Times

Similarly, because patients with bipolar disorder often self-medicate, looking for a family history of substance abuse can be helpful. “iI's Our options are more limited when it comes to bipolar depression, and we do have some agents that are FDA approved specifically for bipolar depression.” References 1.

article thumbnail

FDA Requires New Label Warning of Weight Loss Risk in Pediatric Patients Taking Extended-Release Stimulants for ADHD

Psychiatric Times

3 References 1. According to a national survey, an estimated 7 million (11.4%) US children aged 3-17 years have ever been diagnosed with ADHD and approximately half of children with ADHD (53.6%) received ADHD medication. FDA Drug Safety Communication. June 30, 2025.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NRx Pharmaceuticals Applies for FDA National Priority Voucher for Intravenous Ketamine (NRX-100)

Psychiatric Times

References NRx Pharmaceuticals, Inc. Related Videos Related Content Advertisement June 17th 2025 ADHD With Bipolar Disorder: Genetics, Diagnosis, and New Thinking on Treatment David N. 1 Follow PsychiatricTimes.com for more breaking news as well as expert clinical commentary. Press release. June 23, 2025. Subscribe Now!

article thumbnail

sNDA Submitted: Lumateperone for the Prevention of Relapse in Schizophrenia

Psychiatric Times

An sNDA for Caplyta as an adjunctive treatment for adults with major depressive disorder (MDD) is also currently under FDA review, submitted back in December 2024. References 1. points (effect size 0.61) in study 501 and 4.5 points (effect size 0.56) vs placebo in study 502. Supplemental new drug application submitted to U.S.

article thumbnail

COMP360 Psilocybin for Treatment-Resistant Depression: Positive Phase 3 Efficacy Data

Psychiatric Times

References 1. After the FDA rejection of Lykos Therapeutics’ midomafetamine (MDMA)-assisted psychotherapy tempered excitement for psychedelic therapeutics, 2 this positive data could generate new momentum. News release. June 23, 2025.

article thumbnail

Tardive Dyskinesia: Treat Functional Impairment, Not the AIMS Score

Psychiatric Times

She has been on an antipsychotic medication to treat her bipolar disorder for 10 years, resulting in stability of mood symptoms that were previously poorly controlled. References 1. How can this be? Let’s review a few case examples. Case 1 “Ms Robbins” is 49 years old and works as a bank teller. BMC Psychiatry. 2025;25(1):407.

article thumbnail

Clinical Trials Versus Clinical Treatment – Key Differences

Real Psychiatry

258) – patients referred to see psychiatrists are generally less healthy, more likely to have chronicity, less likely to adhere to treatment, more likely to have a substance use disorder, and more likely to have medical and psychiatric comorbidity. The number of times a person volunteers for clinical research can be an issue.